ScinoPharm Taiwan obtains Bortezomib for Injection ANDA approval

Share：

Bortezomib for Injection developed and produced by ScinoPharm Taiwan, received the U.S. abbreviated new drug application (ANDA) approval on September 26, 2023. The Company systematically invests and strengthens its development and manufacturing capacities of injection products. Bortezomib Injection is our first injection product developed and manufactured by ScinoPharm Taiwan. By getting this ANDA approval, The Company has shown the capability of developing and manufacturing in-house injectable products. It is also a milestone for us to strengthen the vertical integration of the Company's business.

ScinoPharm's pre-filled syringe and liquid injectable products, and lyophilized injectables passed the FDA's pre-approval on-site inspections in March and October 2022. ScinoPharm even achieved an outstanding result of zero 483 observations in the second inspection. In addition to ScinoPharm's APIs and injection products, contract development and manufacturing is its business's mainstay. Scinopharm will diversify business fields according to our business partner's timeline and explore more potential opportunities in different target markets.

Related Information

May 2026

Latest News

ScinoPharm Taiwan Focuses on Metabolic Syndrome Awareness by Promoting Balanced Plant-Based Meals for Employees

ScinoPharm Taiwan has long focused on therapeutic areas including oncology, hematology, central nervous system disorders, and metabolic diseases, while actively advancing the development of GLP-1 related APIs and Drug Products. In parallel with its commitment to pharmaceutical innovation, the company also places strong emphasis on employee wellness and disease prevention, encouraging colleagues to pay greater attention to their personal health through healthier daily habits.

Centered on the concept of “starting change from the dining table,” ScinoPharm Taiwan optimized its employee cafeteria menu by increasing the proportion of fruits and vegetables, making it easier for employees to adopt balanced dietary habits in their everyday lives. In addition, plant-based foods generally generate lower carbon emissions than animal-based products. Choosing locally sourced fruits and vegetables can further reduce transportation distances, logistics-related emissions, and food storage energy consumption, creating additional environmental benefits and contributing to broader sustainability goals.

As metabolic syndrome and chronic diseases continue to affect younger populations, enhancing health awareness and establishing proper dietary and lifestyle habits have become increasingly important for society as a whole. Through this collaboration, employees are not only encouraged to actively practice healthier behaviors themselves, but also to share concepts of healthy eating and health management with their families and social circles, gradually expanding the positive impact beyond the workplace into households and local communities.

Nov 2025

Latest News

ScinoPharm Taiwan 15th in 2025 CSR “Small Giants”

Honored as a 2025 CSR “Small Giants” top 15 company by CommonWealth Magazine.

Oct 2025

Latest News

ScinoPharm Taiwan Hosts Healing Art Forum in Partnership with Formosa Cancer Foundation

ScinoPharm Taiwan recently held its 16th annual ScinoPharm Art Forum, a long-standing public art and cultural lecture series dedicated to enriching lives through art and dialogue.